| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1042459490 |
| P356 | DOI | 10.2165/00003495-199652050-00010 |
| P698 | PubMed publication ID | 9118822 |
| P50 | author | Alexander Markham | Q4719549 |
| P2093 | author name string | M I Wilde | |
| A Markham | |||
| P2860 | cites work | The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig | Q24681951 |
| Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? | Q33486166 | ||
| Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy | Q33560391 | ||
| The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine | Q34346070 | ||
| Serotonergic mediation of postprandial colonic tonic and phasic responses in humans | Q34378949 | ||
| The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment | Q34403658 | ||
| Pharmacology and preclinical antiemetic properties of ondansetron | Q35349111 | ||
| Ondansetron metabolism and pharmacokinetics | Q35349275 | ||
| Pharmacology of ondansetron | Q35487423 | ||
| Ondansetron quells drug-resistant emesis in theophylline poisoning | Q72608194 | ||
| Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis | Q72632948 | ||
| 5-hydroxytryptamine 3-receptor antagonist modulates gallbladder emptying and motilin release induced by erythromycin | Q72658552 | ||
| Jaundice with ondansetron | Q72683613 | ||
| Modulatory role of 5-HT3 receptors in gastric function and ethanol-induced mucosal damage in rat stomachs | Q72835928 | ||
| Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron | Q72844408 | ||
| Anaphylactoid-anaphylactic reactions associated with ondansetron | Q72939046 | ||
| The effect of a 5-HT3 receptor antagonist, ondansetron, on brain stimulation reward, and its interaction with direct and indirect stimulants of central dopaminergic transmission | Q72957854 | ||
| Effects of acute GR38032F (odansetron), a 5-HT3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons | Q93523877 | ||
| Ondansetron for intractable vertigo complicating acute brainstem disorders | Q95820977 | ||
| Ondansetron: pharmacology of a specific 5HT3-receptor antagonist | Q35561324 | ||
| Ondansetron and related 5-HT3 antagonists: recent advances | Q35644115 | ||
| Serotonin and psychiatric disorders. A key to new therapeutic approaches | Q36111671 | ||
| Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents | Q36459024 | ||
| Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports | Q38566839 | ||
| A pilot study of intravenous ondansetron for hyperemesis gravidarum | Q39465331 | ||
| The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning | Q39469615 | ||
| Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron | Q39476222 | ||
| Treatment of acute gouty arthritis with the 5-hydroxytryptamine antagonist ondansetron | Q39481272 | ||
| Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists | Q39492197 | ||
| Ondansetron in the treatment of intractable nausea associated with theophylline toxicity | Q39494120 | ||
| Ondansetron Clinical Pharmacokinetics | Q40431009 | ||
| The role of 5-HT3 receptors in drug dependence | Q40480633 | ||
| Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting | Q40490584 | ||
| Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse | Q40576772 | ||
| 5HT drugs in animal models of anxiety | Q40601511 | ||
| Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions | Q40621526 | ||
| The breadth of action of the 5-HT3 receptor antagonists. | Q40761408 | ||
| 5-HT3 receptors: pharmacologic and therapeutic aspects | Q41095351 | ||
| Effect of 5-hydroxytryptamine on external carotid nerve activity and its blockade by GR38032F in anesthetized rats | Q41822756 | ||
| An examination of the 5-HT3 receptor mediating contraction and evoked [3H]-acetylcholine release in the guinea-pig ileum | Q42025632 | ||
| 5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats | Q42277669 | ||
| Inhibitory effect of ethanol on the 5-hydroxytryptamine-induced Bezold-Jarisch reflex — involvement of peripheral 5-HT3 receptors | Q42277889 | ||
| Managing an extrapyramidal reaction caused by ondansetron | Q42277940 | ||
| Extrapyramidal reaction caused by ondansetron | Q42500504 | ||
| The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension | Q42562426 | ||
| Dysphoria after treatment with ondansetron | Q42564682 | ||
| Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal. | Q42601432 | ||
| The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety | Q42606450 | ||
| Ondansetron usage in HIV positive patients: a pilot study on the control of nausea and vomiting in patients on high dose co-trimoxazole for Pneumocystis carinii pneumonia | Q42608013 | ||
| Pharmacokinetics of ondansetron in patients with hepatic insufficiency | Q42633540 | ||
| Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of the 5-HT3 receptor antagonists. | Q42692565 | ||
| Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study | Q43310092 | ||
| Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. | Q43328501 | ||
| Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding | Q43559808 | ||
| Ondansetron in carcinoid syndrome | Q44197996 | ||
| Failure of ondansetron to block the discriminative or reinforcing stimulus effects of cocaine in the rat. | Q44410438 | ||
| The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates | Q44750193 | ||
| Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. | Q46026737 | ||
| Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine | Q46598073 | ||
| Activation of 5-HT3 receptors enhances the electrically evoked release of [3H]noradrenaline in rat brain limbic structures | Q48124510 | ||
| Investigation of the role of 5-HT3 receptors in the secretion of prolactin, ACTH and renin | Q48260316 | ||
| Involvement of the serotonergic system in ethanol intake in the rat. | Q48288168 | ||
| 5-HT3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. | Q48347747 | ||
| Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers | Q48588432 | ||
| Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers | Q48591312 | ||
| Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow | Q48650660 | ||
| Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse | Q48895181 | ||
| Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo | Q50166769 | ||
| Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. | Q52271427 | ||
| Ondansetron and opiate craving. A novel pharmacological approach to addiction. | Q52271903 | ||
| Serotoninergic control of gonadotrophin and prolactin secretion in women. | Q52363721 | ||
| Ondansetron in the treatment of theophylline overdose | Q53690011 | ||
| A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. | Q53905620 | ||
| Ondansetron and alcohol pharmacokinetics | Q60644613 | ||
| Effect of Serotonin on the Immunoreactive Thyrotropin-Releasing Hormone Concentrations of the Rat Stomach | Q64971849 | ||
| Ondansetron in carcinoid syndrome | Q67518483 | ||
| Ondansetron and hyperemesis gravidarum | Q67523377 | ||
| Ondansetron to prevent emesis following N-acetylcysteine for acetaminophen intoxication | Q67524440 | ||
| Ondansetron: indications and applications in the paediatric intensive care unit | Q67601842 | ||
| 5-Hydroxytryptamine3-receptor blockade protects against gastric mucosal damage in rats | Q67878676 | ||
| Determination of Ondansetron in Plasma and Its Pharmacokinetics in the Young and Elderly | Q67907197 | ||
| Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers | Q68052423 | ||
| Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats | Q68163258 | ||
| Ondansetron in treatment of schizophrenia | Q68299138 | ||
| Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome | Q68434433 | ||
| The effect of ondansetron on gastric emptying in the conscious rat | Q68442040 | ||
| Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist | Q68444360 | ||
| Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference | Q70778012 | ||
| Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans | Q70978018 | ||
| Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children | Q71563767 | ||
| Extrapyramidal reaction caused by ondansetron | Q71601634 | ||
| Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome--a preliminary study | Q71654293 | ||
| Evidence that the amygdala is involved in the inhibitory effects of 5-HT3 receptor antagonists on alcohol drinking in rats | Q71711586 | ||
| Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex | Q71760170 | ||
| Studies on the effects of certain 5-HT-3 receptor antagonists on ethanol preference and withdrawal seizures in the rat | Q71986323 | ||
| The influence of peripheral or central administration of ondansetron on stress-induced gastric ulceration in rats | Q71994568 | ||
| The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron | Q72019512 | ||
| Upregulated expression of peripheral serotonergic receptors in migraine and cluster headache by sumatriptan | Q72054251 | ||
| Comparison of potencies of 5-HT3 receptor antagonists at inhibiting aversive behavior to illumination and the von Bezold-Jarisch reflex in the mouse | Q72071722 | ||
| Ondasentron in the treatment of diabetic diarrhea | Q72133591 | ||
| Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine | Q72157181 | ||
| Influence of 5-HT3 receptor antagonists in visceromotor and nociceptive responses to rectal distension before and during experimental colitis in rats | Q72166274 | ||
| Ondansetron for symptomatic relief in terminal uraemia | Q72174050 | ||
| Ondansetron and hyperemesis gravidarum | Q72208941 | ||
| Improvement of cholestatic pruritus by ondansetron | Q72218628 | ||
| Treatment of chronic cryptosporidiosis-induced diarrhea with a serotonin receptor antagonist | Q72279872 | ||
| Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum | Q72320780 | ||
| Anaphylactoid reactions associated with ondansetron | Q72365914 | ||
| Ondansetron for pruritus due to cholestasis | Q72379137 | ||
| Psychiatric complications associated with ondansetron | Q72392951 | ||
| Ondansetron for treating nausea and vomiting in the poisoned patient | Q72455171 | ||
| Ondansetron in theophylline overdose | Q72543507 | ||
| Seizure associated with ondansetron | Q72561569 | ||
| [Therapy of generalized tendomyopathy (fibromyalgia) caused by blocking 5-HT3 receptors] | Q72581701 | ||
| Profile of action of 5-HT3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice. | Q51126863 | ||
| Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. | Q51134758 | ||
| Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity? | Q51138018 | ||
| Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. | Q51146628 | ||
| Ondansetron for the treatment of pruritus after spinal opioids. | Q51578521 | ||
| Ascending colon response to feeding: evidence for a 5-hydroxytryptamine-3 mechanism. | Q51588383 | ||
| Ondansetron absorption in adults: effect of dosage form, food, and antacids. | Q51594802 | ||
| A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. | Q51595408 | ||
| Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. | Q51596251 | ||
| Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo. | Q51603877 | ||
| Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies. | Q51615291 | ||
| GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. | Q51616453 | ||
| Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. | Q51619066 | ||
| 5-HT3 receptor modulation of behavior during withdrawal from continuous or intermittent cocaine. | Q51638521 | ||
| Potentiation of physical dependence on diazepam by ondansetron in rats. | Q51645148 | ||
| Effects of serotonergic anxiolytics on physical dependence on diazepam in mice. | Q51655524 | ||
| Parameters of self-administration of cocaine in rats under a progressive-ratio schedule. | Q51661784 | ||
| Cardiovascular stability with rapid intravenous infusion of ondansetron. | Q51664745 | ||
| Ultrashort noninvasive opiate detoxification. | Q51665206 | ||
| Effect of serotonin 5-HT1, 5-HT2, and 5-HT3 receptor antagonists on the prolactin response to restraint and ether stress | Q51683999 | ||
| Effects of cocaine alone and in combination with prazosin or ondansetron on multiple fixed-interval fixed-ratio performance in pigeons | Q51686652 | ||
| GR38032F, a serotonin 5-HT3 antagonist, fails to alter cocaine self-administration in rats. | Q51713094 | ||
| The effects of ondansetron (GR38032F) in rats and mice treated subchronically with diazepam. | Q51745563 | ||
| Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. | Q52024450 | ||
| Comparison of the effects of the 5-HT3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system. | Q52048174 | ||
| Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. | Q52052069 | ||
| Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans. | Q52052081 | ||
| Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. | Q52057066 | ||
| A study to evaluate the effect of ondansetron on psychomotor performance after repeated oral dosing in healthy subjects | Q52103647 | ||
| Serotonin 5-HT3 antagonists fail to affect ethanol self-administration of rats. | Q52214866 | ||
| Influence of 5-HT3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats. | Q52217110 | ||
| Effect of 5-HT3 receptor antagonists on the discriminative stimulus properties of morphine in rats. | Q52228710 | ||
| Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset | Q52231738 | ||
| 5-HT3 receptor antagonists reverse helpless behaviour in rats | Q52232621 | ||
| Effects of the 5-HT3 antagonist ondansetron on benzodiazepine-induced operant behavioural dependence in rats. | Q52234544 | ||
| The effect of ondansetron on cognitive performance in the marmoset | Q52238849 | ||
| Effect of drugs influencing 5-HT function on ethanol drinking and feeding behaviour in rats: studies using a drinkometer system. | Q52265125 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 773-794 | |
| P577 | publication date | 1996-11-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications | |
| P478 | volume | 52 |
| Q33856568 | 5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review |
| Q39294002 | 5-HT3 receptors: A potential therapeutic target for epilepsy |
| Q45061444 | A preliminary study of the efficacy of ondansetron in the treatment of ataxia, poor balance and incoordination from brain injury |
| Q35071475 | A review of 25 years of the social interaction test |
| Q42690847 | A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice |
| Q36904890 | Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy |
| Q34312351 | Advances in treating acute myeloid leukemia |
| Q42590441 | Assessment of ondansetron-associated hypokalemia in pediatric oncology patients |
| Q39820388 | Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines |
| Q35074324 | Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting |
| Q36718053 | Candidate genes for antidepressant response to selective serotonin reuptake inhibitors |
| Q44333120 | Chronic pain and ultrarapid opioid detoxification |
| Q39042372 | Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting |
| Q35605831 | Comparison of alcoholism subtypes as moderators of the response to sertraline treatment |
| Q45713757 | Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? |
| Q41563060 | Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery |
| Q51474335 | Effects of ondansetron on gastric tone and motility changes induced by a prolonged intraduodenal infusion of nutrients. Results of a placebo-controlled study. |
| Q42162464 | Enhanced 5-HT(2A) receptor status in the hypothalamus and corpus striatum of ethanol-treated rats |
| Q50966263 | Evaluation of anticonvulsant and nootropic effect of ondansetron in mice. |
| Q34191975 | Extrapyramidal Reactions to Ondansetron: Cross-Reactivity Between Ondansetron and Prochlorperazine? |
| Q42068178 | Extrapyramidal side effects after metoclopramide administration in a post-anesthesia care unit -A case report-. |
| Q43790339 | Failure of ondansetron in treating cerebellar tremor in MS patients--an open-label pilot study |
| Q34481528 | Irritable bowel syndrome: an update on therapeutic modalities |
| Q38614128 | Laparoscopic surgery: a narrative review of pharmacotherapy in pain management |
| Q44340894 | Mirtazapine for pruritus |
| Q37946545 | Nasal route: an alternative approach for antiemetic drug delivery |
| Q37021326 | New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins |
| Q36600684 | Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects |
| Q42628440 | Ondansetron to treat pruritus due to cholestatic jaundice |
| Q42717373 | Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: in vitro/in vivo studies |
| Q43171584 | Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes |
| Q34298900 | Ondansetron: a review of its use as an antiemetic in children |
| Q34320153 | Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. |
| Q30490604 | Pharmacodynamics of memantine: an update |
| Q24202000 | Pharmacological interventions for pruritus in adult palliative care patients |
| Q24241586 | Pharmacological interventions for pruritus in adult palliative care patients |
| Q36193800 | Pharmacological interventions for pruritus in adult palliative care patients. |
| Q34146983 | Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm? |
| Q52021675 | Placental transfer of ondansetron during early human pregnancy. |
| Q44006893 | Prophylactic ondansetron is effective in the treatment of nausea and vomiting but not on pruritus after cesarean delivery with intrathecal sufentanil-morphine |
| Q37099029 | Pruritus and fatigue associated with liver disease: is there a role for ondansetron? |
| Q44852166 | Relative bioavailability of an extemporaneous ondansetron 4-mg capsule formulation versus solution |
| Q30435306 | Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment |
| Q38570496 | Safety and efficacy of commonly used antiemetics |
| Q38794290 | Safety of treatment for gastroparesis |
| Q33951128 | The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner |
| Q92535622 | The Pharmacology of Visual Hallucinations in Synucleinopathies |
| Q37685759 | The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? |
| Q37924850 | The in vivo neurochemistry of the brain during general anesthesia |
| Q24635649 | Treating nausea and vomiting in palliative care: a review |
| Q73535880 | Treatment of chronic bulimic symptoms: new answers, more questions |
| Q44149049 | Treatment of intractable hyperemesis gravidarum by ondansetron. |
| Q58700987 | Tricyclic antidepressant amitriptyline inhibits 5-hydroxytryptamine 3 receptor currents in NCB-20 cells |
| Q39745347 | Unique susceptibility of a human lung carcinoid tumor cell line to infection with BK virus |
Search more.